Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I

Anne E. O'Donnell, Alan Barker, Jonathan S. Ilowite, Robert B. Fick

Research output: Contribution to journalArticle

269 Citations (Scopus)

Abstract

Study objective: To study, the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis. Design: Double-blind, randomized, placebo-controlled, multicenter study. Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland. Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period. Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial. Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.

Original languageEnglish (US)
Pages (from-to)1329-1334
Number of pages6
JournalChest
Volume113
Issue number5
StatePublished - 1998

Fingerprint

Bronchiectasis
Deoxyribonuclease I
Placebos
Outpatients
Therapeutics
Lung
North America
Ireland
Cystic Fibrosis
Multicenter Studies
dornase alfa
Safety
Incidence
Population

Keywords

  • Bronchiectasis
  • COPD
  • Expectorants
  • Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

O'Donnell, A. E., Barker, A., Ilowite, J. S., & Fick, R. B. (1998). Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest, 113(5), 1329-1334.

Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. / O'Donnell, Anne E.; Barker, Alan; Ilowite, Jonathan S.; Fick, Robert B.

In: Chest, Vol. 113, No. 5, 1998, p. 1329-1334.

Research output: Contribution to journalArticle

O'Donnell, AE, Barker, A, Ilowite, JS & Fick, RB 1998, 'Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I', Chest, vol. 113, no. 5, pp. 1329-1334.
O'Donnell, Anne E. ; Barker, Alan ; Ilowite, Jonathan S. ; Fick, Robert B. / Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. In: Chest. 1998 ; Vol. 113, No. 5. pp. 1329-1334.
@article{b3332ea15a4c47d893a2819f7a5f5366,
title = "Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I",
abstract = "Study objective: To study, the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis. Design: Double-blind, randomized, placebo-controlled, multicenter study. Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland. Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period. Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial. Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.",
keywords = "Bronchiectasis, COPD, Expectorants, Therapy",
author = "O'Donnell, {Anne E.} and Alan Barker and Ilowite, {Jonathan S.} and Fick, {Robert B.}",
year = "1998",
language = "English (US)",
volume = "113",
pages = "1329--1334",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I

AU - O'Donnell, Anne E.

AU - Barker, Alan

AU - Ilowite, Jonathan S.

AU - Fick, Robert B.

PY - 1998

Y1 - 1998

N2 - Study objective: To study, the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis. Design: Double-blind, randomized, placebo-controlled, multicenter study. Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland. Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period. Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial. Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.

AB - Study objective: To study, the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis. Design: Double-blind, randomized, placebo-controlled, multicenter study. Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland. Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period. Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial. Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.

KW - Bronchiectasis

KW - COPD

KW - Expectorants

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0031901989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031901989&partnerID=8YFLogxK

M3 - Article

C2 - 9596315

AN - SCOPUS:0031901989

VL - 113

SP - 1329

EP - 1334

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -